Label: POTASSIUM CITRATE AND CITRIC ACID- potassium citrate and citric acid monohydrate solution

  • NDC Code(s): 0121-0676-16
  • Packager: Pharmaceutical Associates, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated August 2, 2017

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    Rx ONLY

  • DESCRIPTION

    Potassium Citrate and Citric Acid Oral Solution USP is a stable and pleasant-tasting oral systemic alkalizer containing potassium citrate and citric acid in a sugar-free, non-alcoholic base.

    Potassium Citrate and Citric Acid Oral Solution USP contains in each teaspoonful (5 mL):

    POTASSIUM CITRATE           Monohydrate  1100 mg

    CITRIC ACID           Monohydrate  334 mg

    Each mL contains 2 mEq potassium ion and is equivalent to 2 mEq bicarbonate (HCO 3).

    Inactive Ingredients: FD&C Red No. 40, flavoring, polyethylene glycol, propylene glycol, purified water, sodium benzoate, and sorbitol solution.

  • ACTIONS

    Potassium citrate is absorbed and metabolized to potassium bicarbonate, thus acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of the potassium citrate is excreted in the urine unchanged.

  • INDICATIONS AND USAGE

    Potassium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. This product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting and tolerable, even when administered for long periods. Potassium citrate does not neutralize the gastric juice or disturb digestion.

  • CONTRAINDICATIONS

    Severe renal impairment with oliguria or azotemia, untreated Addison's disease, adynamia episodica hereditaria, acute dehydration, heat cramps, anuria, severe myocardial damage, and hyperkalemia from any cause.

  • WARNINGS

    Large doses may cause hyperkalemia and alkalosis, especially in the presence of renal disease. Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity.

  • PRECAUTIONS

    Should be used with caution by patients with low urinary output unless under the supervision of a physician. As with all liquids containing a high concentration of potassium, patients should be directed to dilute adequately with water to minimize the possibility of gastrointestinal injury associated with the oral ingestion of concentrated potassium salt preparations; and preferably, to take each dose after meals to avoid saline laxative effect.

  • ADVERSE REACTIONS

    Potassium Citrate and Citric Acid Oral Solution USP is generally well tolerated without any unpleasant side effects when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis. Potassium intoxication causes listlessness, weakness, mental confusion, tingling of extremities, and other symptoms associated with a high concentration of potassium in the serum. Periodic determinations of serum electrolytes should be carried out in those patients with renal disease in order to avoid these complications. Hyperkalemia may exhibit the following electrocardiographic abnormalities: Disappearance of the P wave, widening and slurring of QRS complex, changes of the S-T segment, tall peaked T waves, etc.

  • OVERDOSAGE

    The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, hyperkalemia can result (see Contraindications and Warnings). Hyperkalemia, when detected, must be treated immediately because lethal levels can be reached in a few hours.

  • TREATMENT OF HYPERKALEMIA

    Should hyperkalemia occur, treatment measures include the following: (1) Elimination of foods or medications containing potassium. (2) The intravenous administration of 300 to 500 mL/hr of dextrose solution (10 to 25%), containing 10 units of insulin/20 gm dextrose. (3) The use of exchange resins, hemodialysis, or peritoneal dialysis. In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the plasma potassium concentration can produce digitalis toxicity.

  • DOSAGE AND ADMINISTRATION

    Potassium Citrate and Citric Acid Oral Solution USP should be taken diluted in water according to directions, followed by additional water, if desired. Palatability is enhanced if chilled before taking.

    Usual Adult Dose

    3 to 6 teaspoonfuls (15 to 30 mL), diluted with 1 glass of water, after meals and at bedtime, or as directed by a physician.

    Usual Pediatric Dose

    1 to 3 teaspoonfuls (5 to 15 mL), diluted with 1/2 glass of water, after meals and at bedtime, or as directed by a physician.

    Usual Dosage Range

    2 to 3 teaspoonfuls (10 to 15 mL), diluted with a glassful of water, taken four times a day. Potassium Citrate and Citric Acid Oral Solution USP, diluted with a glassful of water, taken four times a day will usually maintain a urinary pH of 7.0-7.6 throughout most of the 24 hours without unpleasant side effects. To check urinary pH, HYDRION Paper (pH 6.0-8.0) or NITRAZINE Paper (pH 4.5-7.5) are available and easy to use.

  • HOW SUPPLIED

    Potassium Citrate and Citric Acid Oral Solution USP (clear pink to red colored; berry-citrus flavored) is supplied in the following oral dosage form:

    NDC 0121-0676-16: 16 fl oz (473 mL) bottle

    STORAGE

    Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F). Protect from excessive heat and freezing.

  • MANUFACTURED BY

    Pharmaceutical
    Associates, Inc.
    Greenville, SC 29605
    www.paipharma.com

    R03/17

  • PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

    NDC 0121-0676-16

    Potassium Citrate
    and Citric Acid
    Oral Solution USP
    1100 mg/334 mg per 5 mL

    A SUGAR-FREE SYSTEMIC ALKALIZER

    Each teaspoonful (5 mL) contains:
    Potassium Citrate Monohydrate…..1100 mg
    Citric Acid Monohydrate…..334 mg

    Each mL contains 2 mEq Potassium Ion, and is
    equivalent to 2 mEq Bicarbonate (HCO3).

    Rx ONLY

    16 fl oz (473 mL)

    Pharmaceutical
    Associates, Inc.

    Greenville, SC 29605

    INDICATIONS AND USAGE:  Potassium
    Citrate and Citric Acid Oral Solution USP
    is a stable and pleasant-tasting oral
    systemic alkalizer. It is effective for long-
    term maintenance of an alkaline urine,
    especially when the administration of
    sodium salts is undesirable or contra-
    indicated.

    SEE ACCOMPANYING LITERATURE

    DOSAGE AND ADMINISTRATION:

    Usual Adult Dosage:  3 to 6 teaspoonfuls
    (15 to 30 mL) DILUTED with 1 glass of
    water, after meals and at bedtime, or as
    directed by a physician.

    SHAKE WELL BEFORE USING.

    STORAGE:  Keep tightly closed. Store at
    controlled room temperature. 20° -25° C
    (68° -77° F). Protect from excessive heat or
    freezing.

    Dispense in a tight, light-resistance container
    with a child-resistant closure.

    L06761600
    R08/14

    473 mL Bottle Label

  • INGREDIENTS AND APPEARANCE
    POTASSIUM CITRATE AND CITRIC ACID 
    potassium citrate and citric acid monohydrate solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0121-0676
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    POTASSIUM CITRATE (UNII: EE90ONI6FF) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL) POTASSIUM CITRATE1100 mg  in 5 mL
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP) (ANHYDROUS CITRIC ACID - UNII:XF417D3PSL) ANHYDROUS CITRIC ACID334 mg  in 5 mL
    Inactive Ingredients
    Ingredient NameStrength
    SORBITOL (UNII: 506T60A25R)  
    PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
    SODIUM BENZOATE (UNII: OJ245FE5EU)  
    POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)  
    FD&C RED NO. 40 (UNII: WZB9127XOA)  
    WATER (UNII: 059QF0KO0R)  
    Product Characteristics
    ColorredScore    
    ShapeSize
    FlavorBERRYImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0121-0676-16473 mL in 1 BOTTLE; Type 0: Not a Combination Product10/07/1997
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    unapproved drug other10/07/1997
    Labeler - Pharmaceutical Associates, Inc. (044940096)
    Establishment
    NameAddressID/FEIBusiness Operations
    Pharmaceutical Associates, Inc.097630693manufacture(0121-0676)